Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies

Onco Targets Ther. 2014 Feb 21:7:333-42. doi: 10.2147/OTT.S34641. eCollection 2014.

Abstract

In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an important role in the pathogenesis and survival advantage in hematologic malignancies, such as leukemia, lymphoma, and myeloma. The objectives of the present review, hence, are to describe the current knowledge on the PI3K pathway and its isoforms, and to summarize preclinical and clinical studies using PI3K inhibitors, focusing on the advances made in hematologic malignancies.

Keywords: inhibitors; leukemia; lymphoma; myeloma; phosphatidylinositol-3-kinase pathway.

Publication types

  • Review